Strand Life Sciences Launches South Asia’s First Olink Explore HT Proteomics Service
Advertisement
The service enables the measurement of over 5,400 protein biomarkers from just 2 µL of sample, supporting multi-omics research by integrating proteomics with genomics and clinical data for research and drug discovery.
Bengaluru based Strand Life Sciences has launched the Olink Explore HT proteomics service in South Asia, introducing a high-throughput platform for large-scale protein analysis in the region.
The service enables the measurement of over 5,400 protein biomarkers from just 2 µL of sample, supporting multi-omics research by integrating proteomics with genomics and clinical data for research and drug discovery.
The platform is based on Olink’s proximity extension assay (PEA) technology, which allows for sensitive and scalable protein detection across diverse sample types.
With this launch, Strand expands its capabilities to generate large, multi-modal datasets across populations in India, South Asia, and the Middle East. Through its network of clinical partners, the company supports studies across therapeutic areas such as oncology, nephrology, metabolic diseases, and rare disorders.
Speaking on the announcement, Dr. Ramesh Hariharan, CEO, Strand Life Sciences, said, “With Olink Explore HT, Strand is bringing one of the world’s most advanced proteomics platforms to India and the region. By combining this with established strengths in genomics, bioinformatics, and clinical partnerships, Strand aims to deliver end-to-end multi-omics programmes and enable faster, more impactful discovery. We welcome collaborations with global pharma and biotech partners to accelerate research and development pipelines.”
The service enables integrated workflows from study design to data analysis and interpretation, with support for large cohort-based studies.
With access to more than 5,400 protein biomarkers and integration with genomic and clinical datasets, the platform is expected to support discovery, validation, and translational research programmes for academic, pharmaceutical, and biotechnology organizations operating at scale.
Stay tuned for more such updates on Digital Health News
